Ascendis Pharma Endocrinology Division A/S — Credit Rating and Financial Key Figures
CVR number: 32323537
Tuborg Boulevard 12, 2900 Hellerup
Income statement (kEUR)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | 157 401.00 | 122 880.00 | |||
| Costs of manufacturing | -54 319.00 | -39 996.00 | |||
| Gross profit | 103 082.00 | 82 884.00 | |||
| Costs of management | -9 822.00 | -39 673.00 | |||
| Other operating expenses | - 131 569.00 | - 110 886.00 | |||
| EBIT | -98 595.00 | -86 977.00 | - 190 155.00 | -38 309.00 | -67 675.00 |
| Other financial income | 1 559.00 | 12 042.00 | |||
| Other financial expenses | -24 245.00 | -65 699.00 | |||
| Pre-tax profit | - 107 518.00 | -98 887.00 | - 205 626.00 | -60 995.00 | - 121 332.00 |
| Income taxes | 92.00 | 214.00 | |||
| Net earnings | - 107 518.00 | -98 887.00 | - 205 626.00 | -60 903.00 | - 121 118.00 |
Assets (kEUR)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Machinery and equipment | 96.00 | 74.00 | |||
| Tangible assets total | 96.00 | 74.00 | |||
| Other receivables | 44 038.00 | 43 224.00 | 55 415.00 | ||
| Investments total | 44 038.00 | 43 224.00 | 55 415.00 | ||
| Non-current loans receivable | 22 504.00 | 22 504.00 | |||
| Long term receivables total | 22 504.00 | 22 504.00 | |||
| Inventories total | |||||
| Current trade debtors | 760.00 | 533.00 | |||
| Current amounts owed by group member comp. | 44 853.00 | ||||
| Prepayments and accrued income | 1 429.00 | 1 458.00 | |||
| Current other receivables | 688.00 | ||||
| Short term receivables total | 47 042.00 | 2 679.00 | |||
| Cash and bank deposits | 32 572.00 | 39.00 | |||
| Cash and cash equivalents | 32 572.00 | 39.00 | |||
| Balance sheet total (assets) | 44 038.00 | 43 224.00 | 55 415.00 | 102 214.00 | 25 296.00 |
Equity and liabilities (kEUR)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Share capital | - 410 310.00 | - 509 197.00 | - 714 823.00 | 134.00 | 134.00 |
| Retained earnings | 107 518.00 | 98 887.00 | 205 626.00 | - 714 957.00 | - 775 860.00 |
| Profit of the financial year | - 107 518.00 | -98 887.00 | - 205 626.00 | -60 903.00 | - 121 118.00 |
| Shareholders equity total | - 410 310.00 | - 509 197.00 | - 714 823.00 | - 775 726.00 | - 896 844.00 |
| Non-current loans from credit institutions | 138 377.00 | 142 008.00 | |||
| Non-current owed to group member | 732 422.00 | 759 354.00 | |||
| Non-current accruals and deferred income | 5 949.00 | 5 000.00 | |||
| Non-current liabilities total | 876 748.00 | 906 362.00 | |||
| Current loans from credit institutions | 14 828.00 | ||||
| Other non-interest bearing current liabilities | 9.00 | 14.00 | |||
| Accruals and deferred income | 1 183.00 | 936.00 | |||
| Current liabilities total | 1 192.00 | 15 778.00 | |||
| Balance sheet total (liabilities) | - 410 310.00 | - 509 197.00 | - 714 823.00 | 102 214.00 | 25 296.00 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.